BioScrip (BIOS) : Traders are bullish on BioScrip (BIOS) as it has outperformed the S&P 500 by a wide margin of 0.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.58%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.63% in the last 1 week, and is up 1.11% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.33% and the 50-Day Moving Average is 3.97%. BioScrip (NASDAQ:BIOS): On Fridays trading session , Opening price of the stock was $2.69 with an intraday high of $2.81. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.64. However, the stock managed to close at $2.73, a loss of 0.73% for the day. On the previous day, the stock had closed at $2.75. The total traded volume of the day was 566,769 shares.
The company Insiders own 3.6% of BioScrip shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 107.14% . Institutional Investors own 94.17% of BioScrip shares. During last six month period, the net percent change held by insiders has seen a change of 107.14%.
BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.